Compare Adaptive Biotechnologies Corp (ADPT) vs Albemarle Corp. (ALB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Albemarle Corp. — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while Albemarle Corp. trades at $132 (market cap $15.27B). The key difference: Albemarle Corp. is far larger — about 3.8× Adaptive Biotechnologies Corp's market cap, and Albemarle Corp. pays a 1.27% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | ALB | |
|---|---|---|
Market Cap | $4.04B | $15.27B |
Sector | Health | Basic Materials |
52-Week High | $25.45 | $215.62 |
52-Week Low | $12.30 | $72.58 |
Enterprise Value | $4.10B | $17.75B |
Dividend Yield | — | 1.27% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Albemarle Corp.
Albemarle is the world's largest lithium producer. Our outlook for robust lithium demand is predicated upon increased demand for electric vehicle batteries. Albemarle produces lithium from its salt brine deposits in Chile and the U.S. and its hard rock joint venture mines in Australia. Albemarle is also a global leader in the production of bromine, used in flame retardants. The company is also a major producer of oil refining catalysts.
Read more on ALB →
